Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia

Recently, as we experienced a case of extranodal NHL originating from the masseter musclecompletely cured by chemotherapy with radiotherapy, we present the clinical, US, CT, andMR imaging findings in additional one case of biopsy-proved extranodal NHL (NK/T celllymphoma) involving predominantly the masseter muscle also review thoroughly our collectedcases of primary non-Hodgkin’s lymphoma involving the muscles of mastication and facialexpression. On the basis of our comprehensive review, we suggest two conclusions. First, primarymuscle lymphoma particularly originating from muscles of mastication and facial expression isextremely rare, but primary muscle lymphoma should be considered in the differential diagnosisof muscular masses. Second, primary muscle lymphoma particularly originating from muscles ofmastication and facial expression has similar clinical and radiological characteristics to primaryskeletal muscle lymphoma involving other sites. However, the prognosis is more favorablein primary muscle lymphoma originating from muscles of mastication and facial expressioncompared to primary skeletal muscle lymphoma involving other sites. Bangladesh Journal of Medical Science Vol.20(1) 2021 p.181-186

Download Full-text

Clinical characteristics of non-hodgkin's lymphoma as a second primary tumor: a population-based survey

Leukemia & Lymphoma ◽

10.3109/10428199609051621 ◽

1996 ◽

Vol 20 (3-4) ◽

pp. 297-301 ◽

Cited By ~ 5

Author(s):

Eliezer Robinson ◽

Rachel Bar-Deroma ◽

Ron Epelbaum ◽

Gad Rennert ◽

Alfred I. Neugut

Keyword(s):

Primary Tumor ◽

Hodgkin’S Lymphoma ◽

Clinical Characteristics ◽

Population Based ◽

Hodgkin's Lymphoma ◽

Second Primary ◽

Second Primary Tumor ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Population Based Survey

Download Full-text

Second primary malignancies after ocular adnexal lymphoma diagnosis

BMC Ophthalmology ◽

10.1186/s12886-021-01921-7 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Asad Loya ◽

Vignesh Ramachandran ◽

Talha Ayaz ◽

Christina Y. Weng

Keyword(s):

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Secondary Malignancy ◽

Second Primary ◽

Secondary Malignancies ◽

Ocular Adnexal Lymphoma ◽

Non Hodgkin’S Lymphoma ◽

Increased Risk ◽

Non Hodgkin's Lymphoma ◽

Second Primary Malignancies

Abstract Background Although studies have investigated the risk of second primary malignancies (SPMs) associated with lymphoma of various sites, limited studies have investigated this risk in patients with lymphoma originating within the ocular adnexa. We conducted a retrospective study to assess incidence of secondary malignancies in patients with a prior diagnosis of ocular adnexal lymphoma (OAL) and to determine latency periods and age-groups at increased risk for SPM occurrence. Methods Retrospective analysis was performed on data obtained from Surveillance, Epidemiology, and End Results (SEER) 9 database. Patients with an initial primary malignancy diagnosis of OAL between 1973 and 2015 were included in the study. Standardized incidence ratios (SIR) and excess absolute risks (EAR) compared to a SEER reference population with similar sex, race, age, and calendar year were computed for SPMs. Excess absolute risk is per 10,000 individuals; alpha of 0.05 was used. Results Of 1834 patients with primary ocular adnexal lymphoma, 279 developed a secondary malignancy during average follow-up of 110.03 months (+/− 88.46), denoting higher incidence than expected (SIR 1.20; 95% CI, 1.07 to 1.35; EAR 30.56). Amongst the primary lymphoma cohort, 98.7% (1810/1834) of patients had non-Hodgkin’s lymphoma and amongst those that developed secondary malignancies, 99.6% (278/279) had non-Hodgkin’s lymphoma. Patients exhibited increased incidence of lymphohematopoietic and non-lymphohematopoietic second malignancies and no secondary malignancies of the eye or orbit. Patients had increased incidence of secondary malignancies in the first year (SIR 2.07; 95% CI, 1.49 to 2.79; EAR 150.37) and 1–5 years following lymphoma diagnosis (SIR 1.24; 95% CI, 1.01 to 1.51; EAR 34.89). Patients with various OAL subtypes demonstrated differing patterns of site-specific and overall SPM risk. Conclusions Patients with prior diagnosis of ocular adnexal lymphoma possess increased risk of hematologic and non-hematologic secondary malignancies. Risk of secondary malignancy could vary by lymphoma subtype. Patients with ocular adnexal lymphoma may benefit from regular surveillance to promote early detection of second primary malignancies.

Download Full-text